Condensed Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Dec. 31, 2022	$ (7,151)	$ 1	$ 229,759	$ (236,911)
Balance (in Shares) at Dec. 31, 2022		1,228,540
Increase (Decrease) in Shareholders' Equity (Deficit)
Stock-based compensation expense	484		484
Issuance of common stock and warrants, net of offering costs	4,099		4,099
Issuances of common stock and warrants, net of offering costs (in shares)		45,146
Net loss	(8,504)			(8,504)
Balance at Mar. 31, 2023	(11,072)	$ 1	234,342	(245,415)
Balance (in Shares) at Mar. 31, 2023		1,273,686
Balance at Dec. 31, 2022	(7,151)	$ 1	229,759	(236,911)
Balance (in Shares) at Dec. 31, 2022		1,228,540
Increase (Decrease) in Shareholders' Equity (Deficit)
Net loss	(14,790)
Balance at Jun. 30, 2023	$ (15,739)	$ 1	235,961	(251,701)
Balance (in Shares) at Jun. 30, 2023	1,403,776
Balance at Mar. 31, 2023	$ (11,072)	$ 1	234,342	(245,415)
Balance (in Shares) at Mar. 31, 2023		1,273,686
Increase (Decrease) in Shareholders' Equity (Deficit)
Stock-based compensation expense	502
Issuance of common stock, net of offering costs	1,074		1,074
Issuances of common stock, net of offering costs (in shares)		128,510
Issuance of common stock under equity plans	43		43
Issuance of common stock under equity plans (in shares)		1,580
Net loss	(6,286)			(6,286)
Balance at Jun. 30, 2023	$ (15,739)	$ 1	235,961	(251,701)
Balance (in Shares) at Jun. 30, 2023	1,403,776
Balance at Dec. 31, 2023	$ (809)	$ 2	239,688	(240,499)
Balance (in Shares) at Dec. 31, 2023		2,285,818
Increase (Decrease) in Shareholders' Equity (Deficit)
Stock-based compensation expense	383		383
Issuance of common stock, net of offering costs	1,832	$ 1	1,831
Issuances of common stock, net of offering costs (in shares)		375,989
Net loss	(3,168)			(3,168)
Balance at Mar. 31, 2024	(1,762)	$ 3	241,902	(243,667)
Balance (in Shares) at Mar. 31, 2024		2,661,807
Balance at Dec. 31, 2023	(809)	$ 2	239,688	(240,499)
Balance (in Shares) at Dec. 31, 2023		2,285,818
Increase (Decrease) in Shareholders' Equity (Deficit)
Net loss	(6,007)
Balance at Jun. 30, 2024	(3,089)	$ 3	243,414	(246,506)
Balance (in Shares) at Jun. 30, 2024		3,407,564
Balance at Mar. 31, 2024	(1,762)	$ 3	241,902	(243,667)
Balance (in Shares) at Mar. 31, 2024		2,661,807
Increase (Decrease) in Shareholders' Equity (Deficit)
Stock-based compensation expense	339		339
Issuance of common stock, net of offering costs	1,172		1,172
Issuances of common stock, net of offering costs (in shares)		745,057
Issuance of common stock under equity plans	1		1
Issuance of common stock under equity plans (in shares)		700
Net loss	(2,839)			(2,839)
Balance at Jun. 30, 2024	$ (3,089)	$ 3	$ 243,414	$ (246,506)
Balance (in Shares) at Jun. 30, 2024		3,407,564

Tracon Pharmaceuticals, Inc. 10-Q